Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: Report of four cases

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 11, 2007, Pages 988-994

  Armbrust, Thomas ^a   Sobotta, Michael ^a   Füzesi, Laszlo ^a   Grabbe, Eckhardt ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Colon carcinoma; Primary tumor; Systemic chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CASE REPORT; COLON ADENOMA; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LONG TERM CARE; MALE; PRIORITY JOURNAL; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADENOMA; AGED; ANTINEOPLASTIC AGENTS; COLON; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37349122116     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282efa41f     Document Type: Article

References (22)

1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353:391-399.
2. Lamberti C, Di Blasi K, Archut D, Fimmers R, Mathiak M, Bollmann M, et al. Population-based registration of unselected colorectal cancer patients: five-year survival in the region of Bonn/Rhine-Sieg, Germany. Z Gastroenterol 2005; 43:149-154.
3. Ciccolallo L, Capocaccia R, Coleman MP, Berrino F, Coebergh JW, Damhuis RA, et al. Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut 2005; 54:268-273.
4. Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 2005; 89:211-217.
5. Telbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates Y, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568-573.
6. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic cancer. N Engl J Med 2000; 343:905-914.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
8. DeGramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
9. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 2004; 22:229-237.
10. Miranda E, Destro A, Malesci A, Balladore E, Bianchi P, Baryshnikova E, et al. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 2006; 95:1101-1107.
11. Hirota I, Wang F-Y, Murano M, Indue T, Toshiana K, Nishikawa T, Maemura K. Histopathological and genetic differences between polypoid and nonpolypoid submucosal colorectal carcinoma. World J Gastroent 2007; 13:2048-2052.
12. Cook AD, Single R, McCahill LE. Surgical treatment of primary tumors in patients with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol 2005; 12:637-645.
13. Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Mishelassi F, et al. Initial presentation with stage IV colorectal cancer. How aggressive should we be? Arch Surg 2000; 135:530-534.
14. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6:651-657.
15. Gross CP, Guo Z, Mc Avay GJ, Krumholz HM, Paltiez D, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectaney after a diagnosis of colorectal cancer. Implications for screening. Ann Int Med 2006; 145:646-653.
16. Temple L, Hsieh L, Wong D, Sauz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004; 22:3475-3484.
17. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
18. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma-carcinoma sequence in large bowel. Lancet 1978; 8058:245-247.
19. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg 2005; 9:90-101.
20. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24:668-674.
21. Petrelli NJ. Systemic chemotherapy should be the primary treatment of synchronous colorectal metastases in the asymptomatic patient. Ann Surg Oncol 2006; 3:137-138.
22. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93:872-878.